Search clinical trials for: Irinotecan

Total 1531 results

Yunpeng Liu
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

Biliary Tract Carcinoma

China
Zhou Chengzhi
Guangdong Provincial Hospital of Traditional Chinese Medicine; Sun Yat-sen... and other collaborators

Not yet recruiting

Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer

Small Cell Lung Cancer
Merck Sharp & Dohme LLC
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Not yet recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Cervical Cancer
New Approaches to Neuroblastoma Therapy Consortium
Nationwide Children's Hospital; United Therapeutics; Children's Neuroblastoma...

Not yet recruiting

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Neuroblastoma

United States
Peking University

Recruiting

Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan

Colorectal Cancer | Solid Tumor

China
West China Hospital

Not yet recruiting

Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma

Cholangiocarcinoma
Zhejiang Cancer Hospital

Not yet recruiting

Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer

Gastric Cancer

China
Sun Yat-sen University

Not yet recruiting

Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer

Colorectal Cancer

China
Ba Yi
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

Biliary Tract Carcinoma

China
XIANG YANQUN

Not yet recruiting

Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy

Nasopharyngeal Cancer

China
Pei-Rong Ding
Fujian Cancer Hospital; Shantou Central Hospital; Liaoning Tumor Hospital & Institute and other collaborators

Recruiting

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

Rectal Neoplasms

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine as Conversion Therapy of Locally Advanced Colorectal Cancer

Colorectal Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Pancreatic Adenocarcinoma | Advanced Cancer | Drug Use | Capecitabine | Oxaliplatin | First-Line | Cadonilimab | Nanoliposomal Irinotecan

China
Children's Oncology Group

Not yet recruiting

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Stage I Kidney Wilms Tumor | Stage II Kidney Wilms Tumor | Stage III Kidney Wilms Tumor | Stage IV Kidney Wilms Tumor
Ohio State University

Not yet recruiting

Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)

Preterm Birth | Pregnancy, High Risk | Preterm Premature Rupture of Membrane

United States
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors

Advanced Malignant Neoplasm
Peking Union Medical College Hospital

Not yet recruiting

Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer (undetermined)

Borderline Resectable Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

Efficacy and Safety
Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Adenocarcinoma

United States
Peking Union Medical College Hospital

Not yet recruiting

Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients (MA-PC-RWS-011)

Pancreatic Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC

Intrahepatic Cholangiocarcinoma

China
Fudan University

Not yet recruiting

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment (FD-IMPACT)

Pancreatic Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Sintilimab Plus FOLFIRI as Salvage Therapy for Patients With Advanced Gastric Cancer

Unresectable/Metastatic Gastric Cancer

China
Kuirong Jiang
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

Pancreatic Cancer | Adjuvant Therapy

China
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Gastroesophageal Cancer

United States, Israel, Taiwan, Korea, Republic of
LaNova Medicines Zhejiang Co., Ltd.

Not yet recruiting

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
AstraZeneca

Recruiting

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Gastric Cancer | Gastroesophageal Junction Cancer

Canada, Spain, United Kingdom, China, France, Italy, Vietnam, Germany, United States, India, Taiwan, Thailand, Hong Kong, Japan, Switzerland, Poland
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Borderline Resectable Pancreatic Cancer

China
West China Hospital

Not yet recruiting

Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
West China Hospital

Not yet recruiting

Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
Peking University People's Hospital
Peking University Shougang Hospital; Shandong Cancer Hospital and Institute

Recruiting

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Ewing Sarcoma

China
Baohui Han

Not yet recruiting

Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy

Extensive-stage Small-cell Lung Cancer

China
Beijing Hospital
Bethune Charitable Foundation

Recruiting

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Metastatic Colorectal Cancer | MSS | RAS Mutation

China
National Cancer Institute (NCI)

Not yet recruiting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer

Rectal Cancer

China
Hellenic Institute for the Study of Sepsis

Recruiting

Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT) (REACT)

Community-acquired Pneumonia

Greece
Tianjin Medical University Cancer Institute and...
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer

Metastatic Biliary Tract Cancer

China
Fudan University

Not yet recruiting

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Small Cell Lung Cancer Recurrent

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

Pancreatic Cancer
Fudan University

Recruiting

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer (PTCA199-11)

Pancreatic Adenocarcinoma

China
Qilu Hospital of Shandong University
The Affiliated Hospital of Qingdao University; Shandong Provincial Hospital; Qianfoshan... and other collaborators

Recruiting

Second-line Treatment of Metastatic Colorectal Cancer (BEV-TASIRI)

Metastatic Colorectal Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

China
Shanghai Zhongshan Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Institut de Recherches Internationales Servier

Not yet recruiting

Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas

Metastatic Adenocarcinoma of the Pancreas

Japan
AstraZeneca

Recruiting

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Gastric Cancer | Pancreatic Adenocarcinoma | Gastroesophageal Junction Cancer

United States, Spain, United Kingdom, Korea, Republic of, Canada, Japan, Malaysia, Taiwan, Singapore, Moldova, Republic of, Australia, Poland, Georgia
Hebei Medical University Fourth Hospital

Not yet recruiting

Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

Rectal Cancer
Changhai Hospital

Not yet recruiting

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

Pancreatic Cancer
Australian & New Zealand Children's Haematology...
The Hospital for Sick Children; Kazia Therapeutics Limited; Day One Biopharmaceuticals... and other collaborators

Not yet recruiting

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Childhood Cancer | Refractory Cancer | Recurrent Cancer | Childhood Solid Tumor | Childhood Brain Tumor

Australia, Canada
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients

Metastatic Colorectal Cancer

China

Search clinical trials for: Irinotecan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations